Accueil > Actualité
Actualite financiere : Actualite bourse

AstraZeneca: research into respiratory diseases

( - AstraZeneca presents its latest research on major respiratory and immune diseases at ATS 2024.

AstraZeneca will present new clinical and real-world data on its respiratory inhalation, biologics and early science portfolio.

The company will present 59 abstracts, including 12 late-breaking posters, focusing on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as well as other chronic respiratory diseases.

Sharon Barr, Ph.D., Executive Vice President, Biopharmaceutical R&D at AstraZeneca, said: 'The ATS data demonstrate our progress in advancing a new wave of innovative treatments, going beyond symptom control to disease modification, remission and, one day, potentially cure'.

Ruud Dobber, Ph.D., Executive Vice President and President of AstraZeneca's BioPharmaceuticals Business Unit, said: 'Our broad portfolio of inhaled and biologic medicines is the cornerstone of our bold ambition to transform respiratory care. COPD remains one of the leading causes of death worldwide'.

Copyright (c) 2024 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.